Offering biomedical innovators the experience, expertise, and funding required for success.
Through the RCT Ventures program, venture capital is provided to start-up or early-stage companies with technologies that have the potential to become significant biomedical products with a definite competitive edge. Learn more ›
RCT develops and invests in technologies that enhance and enable the discovery and manufacture of therapeutics and diagnostics. Many of these life science tools are available from RCT through affordable nonexclusive licensing. Learn more ›
TUCSON, Arizona (Business Wire). Research Corporation Technologies (RCT) announces that Gary M. Munsinger, Ph.D., resigned from its Board of Directors and all positions associated with RCT, effective May 15, 2018. Dr. Munsinger was a founding Director of RCT in 1987 … Learn more